Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Summit Therapeutics and Lunit announced a research agreement to apply Lunit's AI-powered SCOPE IO pathology platform to tumor microenvironment analysis in support of Summit's ivonescimab immuno-oncology programs. The work will analyze routine H&E whole-slide images to support biomarker discovery and patient stratification for ivonescimab, a PD-1/VEGF bispecific antibody in 17 Phase III studies. No clinical outcome data were announced and no financial terms were disclosed.
Key figures
- Drug Name
- ivonescimab
- Phase3 studies total
- 17
- Patients treated clinical studies
- over 5,000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.